Diagnostics & medtech

AI-assisted optical coherence tomography and fundus imaging for broad-disease eye screening — diabetic retinopathy, age-related macular degeneration and glaucoma — spanning home-use monitoring devices, multimodal clinic platforms and autonomous AI diagnostic software: Notal Vision and iHealthScreen in the US, Topcon Healthcare (Japan), RetinAI in Switzerland (acquired by EssilorLuxottica), and Airdoc in China.

AI interpretation of digitized whole-slide histology images using self-supervised vision transformers and attention multiple-instance learning to detect tumour foci, grade cancer (Gleason) and predict molecular biomarkers (MSI, PD-L1) from morphology, cutting diagnosis time from days to minutes.

Physical infrastructure for collecting, processing, cryopreserving and distributing human biospecimens at population or clinical-trial scale — the biospecimen logistics layer, not the genomic-data repository itself: UK Biobank in the EU, BioLife Solutions and Discovery Life Sciences in the US, the China National GeneBank in China, and the newly inaugurated Phenome-India National Biobank (CSIR-IGIB) in India.

Non-invasive breath analysis using VOC patterns for early diagnosis and continuous disease monitoring.

Tissue-based immunohistochemistry (IHC) and FISH platforms that determine whether a specific patient is eligible for a specific targeted therapy, sold and regulated as a companion diagnostic (CDx) tied directly to a drug label — distinct from blood-based liquid-biopsy CDx: Ventana/Roche Tissue Diagnostics, Agilent Dako and Myriad Genetics in the US, 3D Medicines in China, and MedGenome in India.

Cas-enzyme nucleic-acid detection — point-of-care molecular diagnostics from sample to lateral-flow readout.

Advanced analytical devices detecting biological markers to enable rapid, precise disease identification and monitoring.

Direct-to-consumer genetic testing from saliva via SNP genotyping arrays and 30x whole-genome sequencing, with bioinformatic polygenic risk scoring and telemedicine gating of pathogenic findings (BRCA1/2), under FDA 510(k), EU IVDR and China's genetic-data sovereignty rules.

Reading DNA-methylation patterns across hundreds of thousands of CpG sites to compute a person's biological age and pace of aging, rather than the calendar age on a birth certificate, turning a $229-799 saliva or blood test into the primary read-out for the longevity industry.

Non-invasive breath-analyte devices aiming to monitor diabetes-relevant metabolic state without a fingerstick or implanted sensor — most commercially advanced platforms detect breath acetone/ketones as a metabolic proxy, while newer entrants target a more direct blood-glucose alert claim: PranaQ, Invoy Technologies, LEVL and PREEVNT, all US-based.

Sequencing-based services that track pathogen genomic evolution and spread for public health response — traveler/airport biosurveillance, portable field sequencing and national metagenomic surveillance programs — the genomic-analysis service layer, not the sample-collection infrastructure: Ginkgo Bioworks (Concentric) in the US, Oxford Nanopore Technologies and the Wellcome Sanger Institute/UKHSA in the UK, BGI Genomics in China, and the Rajiv Gandhi Centre for Biotechnology in India.

Self-administered blood collection for consumer health testing, either mailed to a certified laboratory or drawn at a retail microsample station, returning results outside a clinic visit — distinct from clinic point-of-care testing: LetsGetChecked and Everlywell (mail-in kits) and Babson Diagnostics (retail microsample testing) in the US, and Thriva in the UK.

Surgically or subcutaneously implanted sensors that continuously monitor a chronic-disease parameter for months to years without an external wearable — implantable continuous glucose monitors and insertable cardiac monitors — distinct from external wearables and ingested/swallowed sensors: Senseonics' Eversense 365 in the US, Medtronic's LINQ II and Boston Scientific's LUX-Dx cardiac monitors in the US, Biotronik's BIOMONITOR in Germany, and MicroPort in China.

Swallowed capsule devices that image the GI tract or confirm medication ingestion as they transit the body, requiring no sedation or implantation — distinct from surgically implanted sensors: Medtronic's PillCam and CapsoVision's CapsoCam capsule endoscopy in the US, etectRx's ID-Cap ingestible event marker in the US, and Ankon Technologies' magnetically controlled capsule endoscopy in China.

Real-time, in-the-operating-room molecular and optical tissue identification — fluorescence imaging agents, OCT, stimulated Raman histology and mass-spectrometry tissue analysis — that lets surgeons assess tumor margins during the procedure instead of waiting on frozen-section pathology: On Target Laboratories and Dilon Technologies (fluorescence/RF-spectroscopy margin agents), Perimeter Medical Imaging AI (AI-enabled OCT), Invenio Imaging (stimulated Raman histology) in the US, and photonamic and Imperial College London (iKnife/REIMS) in Europe.

Blood-based detection and quantification of circulating tumor DNA (ctDNA) for cancer companion diagnostics and molecular residual disease (MRD) monitoring, replacing or supplementing tissue biopsy — led by Guardant Health, Natera and Foundation Medicine in the US, Sysmex Inostics in the EU, MedGenome in India, and Burning Rock Biotech in China.

Stool- or swab-based sequencing panels that profile the gut or GI microbiome for consumer wellness insight or clinical pathogen/dysbiosis detection, distinct from general human genomics services: Viome (US, consumer wellness) and Codex Genetics (US, clinical metagenomics), Sequentia Biotech's IVDR-CE-marked MICK Clinical in Spain, Realbio Genomics in China, and Yaazh Xenomics in India.

A single blood draw screening asymptomatic, average-risk individuals for signals of dozens of cancer types simultaneously, aiming to catch cancer before symptoms appear — distinct from treatment-matched companion diagnostics: GRAIL's Galleri (US), Exact Sciences' Cancerguard (US) and Freenome (US), Novigenix in Switzerland, and Singlera Genomics in China.

Integrative genomic, transcriptomic and proteomic oncology profiling platforms that combine multiple molecular data layers into a single treatment-matching report, broader than a single drug-label companion diagnostic: Tempus AI and Caris Life Sciences in the US, Sophia Genetics in Switzerland, Geneseeq Technology in China, and 1cell.ai in India.

Outsourced One Health surveillance that fuses veterinary, human and environmental sampling with shotgun metagenomic sequencing, CARD resistome profiling and AI spillover-risk scoring to detect zoonotic pathogens and antimicrobial resistance, delivered as an ISO 17025 reference-lab service under EU 2003/99/EC, US NARMS and China's containment plan.

Microphysiological systems mimicking human organs in vitro to replace animal testing and accelerate personalized medicine.

Molecular diagnostics leveraging NGS, liquid biopsy, and AI for precision medicine and targeted therapies.

Lab-free, sample-to-answer molecular testing platforms delivering PCR-grade results at the bedside, clinic or field site in minutes rather than the hours a central lab requires: Cepheid's GeneXpert (Danaher) and bioMérieux's BIOFIRE cartridge-based systems, Abbott's ID NOW isothermal platform, Sansure Biotech's domestic POCT scale-up in China, and Molbio Diagnostics' Truenat chip-based platform serving resource-limited settings from India.

Platforms that determine which antibiotics a specific infecting pathogen is susceptible or resistant to in hours instead of the 2-3 days conventional culture-based susceptibility testing requires, guiding targeted rather than empiric antibiotic therapy: Accelerate Diagnostics and T2 Biosystems and Selux Diagnostics in the US, Q-linea in Sweden, and Autobio Diagnostics in China.

Eye-scan technologies that detect Alzheimer's and other neurodegenerative-disease biomarkers directly in the retina — a window onto brain pathology accessible without imaging the brain itself — spanning hyperspectral imaging, OCT-based structural biomarkers and retinal amyloid detection: RetiSpec and NeuroVision Imaging in North America, Optina Diagnostics in Canada, and Heidelberg Engineering in Germany.

Engineered, exogenous reporter molecules — activity-based nanosensors, synthetic gene circuits and volatile-organic-compound probes — administered to a patient to generate an amplified, easily measured disease signal that no endogenous biomarker naturally produces: Glympse Bio, Earli and ZymoSense in the US, and Owlstone Medical's EVOC breath-probe platform in the UK.

Point-of-care diagnostic testing of a microliter tear sample for dry eye, ocular allergy and inflammatory biomarkers, avoiding blood draw or invasive sampling: Trukera Medical's tear osmolarity system and Lacrisciences' tear IgE allergy test and QuidelOrtho's InflammaDry inflammatory marker test in the US, and DiagnosTear's TearX platform in France.

Aggregate, non-invasive molecular surveillance of municipal sewage for pathogens, antimicrobial resistance and substance use — an early-warning public-health intelligence service built on viral concentration, droplet-digital PCR and metagenomic sequencing.

Wearable biodiagnostics and continuous monitoring systems enabling real-time precision health management.